Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

High Immunogenicity of the Pneumococcal Conjugated Vaccine in Immunocompromised Adults With Inflammatory Bowel Disease

Pittet, Laure F. MD-PHD1; Verolet, Charlotte M. MD1; Michetti, Pierre MD2,3; Girardin, Marc MD4; Juillerat, Pascal MD5; Mottet, Christian MD6; Maillard, Michel H. MD-PHD2,3; Siegrist, Claire-Anne MD7; Posfay-Barbe, Klara M. MD, MS1 the Swiss Inflammatory Bowel Disease Cohort Study Group

American Journal of Gastroenterology: July 2019 - Volume 114 - Issue 7 - p 1130–1141
doi: 10.14309/ajg.0000000000000289

INTRODUCTION: Patients with inflammatory bowel disease (IBD) are predisposed to pneumococcal infections due to their underlying disease and iatrogenic immunosuppression. Vaccination with the 13-valent pneumococcal conjugated vaccine (PCV13) is recommended, but with poor take-up and few data available. We performed an open-label, phase IV, multicenter study to evaluate the safety and immunogenicity of PCV13 in adults with IBD and to analyze the influence of immunomodulating treatments on anti-pneumococcal seroresponses.

METHODS: We enrolled 306 patients with IBD from March 2014 through February 2016, with the following exclusion criteria: current IBD flare, pregnancy, pneumococcal immunization in the previous 5 years, and influenza immunization in the previous 4 weeks. PCV13 was administered intramuscularly. Serotype-specific vaccine responses were evaluated using an opsonophagocytic assay. Adverse events were monitored by diary cards and standardized phone interviews.

RESULTS: The median seroprotection rate increased significantly from 43.9% (95% confidence interval [CI], 42.3–45.5) at inclusion to 90.4% (95% CI, 89.5–91.3%; P < 0.001) after vaccination. Patients receiving anti–tumor necrosis factor agents achieved a slightly lower seroprotection rate (from 44.5% [95% CI, 42.3%–46.8%] to 86.6% [95% CI, 84.9%–88.1%]) than patients treated with other types of immunosuppressive regimens (thiopurine, methotrexate, oral corticosteroids; from 44.7% [95% CI, 41.7%–47.7%] to 93.8% [95% CI, 92.1%–95.2%]) or nonimmunosuppressive treatment (5-aminosalicylate, topical corticosteroids, vedolizumab; from 41.3% [95% CI, 37.9%–44.8%] to 95.2% [95% CI, 93.4%–96.6%]). There were no safety issues.

DISCUSSION: Overall, the administration of PCV13 was highly immunogenic and well tolerated, irrespective of the baseline treatment, and should be encouraged in all adults with IBD.

1Pediatric Infectious Disease Unit, Division of General Pediatrics, Department of Pediatrics, Children's Hospital, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland;

2Crohn's and Colitis Center, Gastroenterology Beaulieu SA, Lausanne, Switzerland;

3Service of Gastroenterology and Hepatology, Department of Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland;

4Gastroenterology Service, Department of Medical Specialities, Geneva University Hospitals, Geneva, Switzerland;

5Service of Gastroenterology, Clinic of Visceral Surgery and Medicine, Bern University Hospital, Bern, Switzerland;

6Service of Gastroenterology, Hôpital Cantonal, Sion, Switzerland;

7Departments of Pathology-Immunology and Pediatrics, Centre for Vaccinology, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.

Correspondence: Klara M. Posfay-Barbe, MD, MS. E-mail:

SUPPLEMENTARY MATERIAL accompanies this paper at

Received November 30, 2018

Accepted May 07, 2019

© The American College of Gastroenterology 2019. All Rights Reserved.
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website